1501 W. Beauregard
San Angelo, Texas 76901
Phone: (325) 658-7750
Fax: (325) 658-8381
Crisis: (800) 375-8965
or (325) 653-5933

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Is FDA Taking Close Enough Look at Fast-Tracked Drugs?Steep Price Hikes Led to Drop in Use of 2 Heart Drugs at U.S. HospitalsAPA: Medical Discrimination Based on Size Stresses Patients2 of 3 U.S. Patients Keep Unused Painkillers After SurgeryMedical Reality Catches Up to Science FictionFDA Looks to Reduce Nicotine in CigarettesAHA Hands-Only CPR Training Kiosks Available at More Airports$100 Sweetens the Pot for a ColonoscopyJust a Few Vaccine Refusers Could Endanger ManyASCO Addresses Cancer Drug PricingHigh Court Rules Against Interstate Medical LiabilityFewer U.S. Dollars Spent on Cardiac Arrest Research: StudyPainkiller Prescriptions More Prone to Errors If HandwrittenFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Walking Rates Are Key to a Country's Obesity LevelsDocs Should Counsel Even Healthy People on Diet, Exercise, Experts SayHealth Service Use Unchanged From 1996-1997 to 2011-2012Easier Colon Exam Boosts Screening, But Insurers May Not PayMore U.S. Patients Are Recording Their Doctor VisitsMedication Mistakes Have Doubled in U.S. Since 2000: StudyPatient Involvement Can Cut Errors in X-Ray ImagingMarket Competition Linked to Change in Generic Drug PricesBlood Shortage Prompts Call for DonationsBullying Takes Financial Toll on U.S. School DistrictsPoll Finds Seniors Struggling With Drug Costs Don't Seek HelpMany U.S. Teens Still Denied 'Morning After' Pill at PharmaciesOlder Americans Struggling With Drug Costs Don't Ask for HelpDoctors Urged to Take Care With Electronic CommunicationsClimate Change Likely to Widen Gap Between Rich, Poor in U.S.: StudyFDA Seeks to Increase Number of Generic Drugs on Market3 Simple Steps Might Reduce Opioid OD DeathsPhysician Attitude Important Factor in Patients Switching PCPMany Adverse Events Related to Cosmetics Go UnreportedStudy Highlights the Beauty Industry's Ugly SideMedicaid Cuts Tied to Delayed Breast Cancer DiagnosesPrimary Care Pharmacy Model Attractive to Patients1991-2014 Saw Minimal Change in Health Spending Per StateLegalized Pot May Lead to More Traffic CrashesMany Doctors Silent on Cost of Cancer CareGroup Urges Tougher Limits on Chemical in Shampoos, Cosmetics18 Percent Increase Projected in Primary Care Demand by 2023Why Patients Leave the Hospital Against Doctor's OrdersRaise the Smoking Age to 21? Most Kids Fine With ThatComprehensive Audiologic Care Feasible in Free Clinic ModelMany Tanning Salons Defy Legal Age Limits on UsersLifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyFDA Puts Brakes on Rule Requiring New 'Nutrition Facts' LabelCardiac Arrest? Someday, Drones May Come to Your Rescue
Questions and AnswersLinksBook Reviews
Related Topics

Healthcare

Lifesaving Drugs From Pfizer in Short Supply: FDA

HealthDay News
by -- Margaret Farley Steele
Updated: Jun 16th 2017

new article illustration

FRIDAY, June 16, 2017 (HealthDay News) -- The U.S. Food and Drug Administration said Friday that it's working with the drug company Pfizer to remedy a shortage of important injectable medications, including emergency syringes of epinephrine.

Epinephrine treats anaphylaxis, a severe allergic reaction to bee stings and foods such as peanuts.

The drugs in short supply are made by the Pfizer company Hospira. In some cases, the FDA is extending expiration dates.

"These are all critically important drugs for treating patients with life-threatening conditions," said Dr. Robert Glatter, an emergency physician at Lenox Hill Hospital in New York City.

The conditions these drugs treat include cardiac arrest (when the heart suddenly stops); a chemical imbalance in the blood called metabolic acidosis; and abnormal heart rhythms, Glatter said.

"The reality is this: There is no substitute for medications such as epinephrine in the setting of anaphylaxis, angioedema, and patients in cardiac arrest," Glatter said. "The end result may be death." Angioedema is swelling that can occur as part of a serious allergic reaction.

Besides epinephrine, the drugs include vials and syringes of sodium bicarbonate and dextrose 50 percent injections, as well as emergency syringes of calcium chloride and atropine sulfate.

Pfizer blames the shortage on manufacturing, distribution and third-party delays, the FDA said.

"We are working closely with Pfizer to resolve these critical shortages by addressing the underlying causes," the agency said in a news release.

The FDA said it's seeking alternative manufacturers, and weighing whether to expedite review of new applications.

The FDA has also extended expiration dates on certain lots of emergency syringes, so that health care professionals can continue using them during the shortage.

If replacement syringes become available during the extension period, the FDA said the older lots should be disposed of as soon as possible.

"We will update the public as the situation changes. Continue to visit the drug shortages webpage for more information on approved sources of these drug products," the agency said.

According to Glatter, the FDA's steps are just a temporary fix.

The "shelf life" and potency of these drugs may extend well beyond their intended expiration dates. However, he said it's never ideal to risk a patient's life with a medication that has expired.

"It is imperative that we develop real-world solutions to the dangerous dilemma of critical drug shortages that threaten patients' lives and safety," Glatter added.

To see which syringe lots have extensions, check the FDA's Drug Shortages webpage. Doctors and other health care professionals can also contact Pfizer directly.

More information

For more about anaphylaxis, see the American Academy of Allergy, Asthma, and Immunology.